Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $67.78 per share as of 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2024-03-12
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $67.78.
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $69.02.
- 2023-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $70.47.
- 2023-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $75.45.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2023-12-31 | $67.78 10-K · filed 2024-03-12 |
| 2023-09-30 | $69.02 10-Q · filed 2023-11-07 |
| 2023-06-30 | $70.47 10-Q · filed 2023-08-08 |
| 2023-03-31 | $75.45 10-Q · filed 2023-05-09 |
| 2022-12-31 | $92.55 10-K · filed 2023-03-07 |
| 2022-09-30 | $3.19 10-Q · filed 2022-11-08 |
| 2022-06-30 | $3.28 10-Q · filed 2022-08-09 |
| 2022-03-31 | $3.36 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.14 10-K · filed 2022-03-08 |
| 2021-09-30 | $4.46 10-Q · filed 2021-11-12 |
| 2021-06-30 | $4.47 10-Q · filed 2021-08-12 |
| 2021-03-31 | $4.56 10-Q · filed 2021-05-13 |
| 2020-12-31 | $5.15 10-K · filed 2021-03-15 |
| 2020-09-30 | $5.18 10-Q · filed 2020-11-09 |
| 2020-06-30 | $5.13 10-Q/A · filed 2020-08-31 |
| 2020-03-31 | $5.07 10-Q · filed 2020-05-11 |
| 2019-12-31 | $5.15 10-K · filed 2020-03-16 |
| 2019-09-30 | $3.68 10-Q · filed 2019-11-07 |
| 2019-06-30 | $3.51 10-Q · filed 2019-08-08 |
| 2019-03-31 | $3.32 10-Q · filed 2019-05-09 |
| 2018-09-30 | $2.73 10-Q · filed 2018-11-08 |
| 2018-06-30 | $2.58 10-Q · filed 2018-08-08 |
| 2018-03-31 | $2.41 10-Q · filed 2018-05-10 |
| 2017-12-31 | $1.98 10-K · filed 2018-03-12 |
| 2017-09-30 | $1.61 10-Q · filed 2017-11-08 |
| 2017-06-30 | $1.36 10-Q · filed 2017-08-09 |
| 2017-03-31 | $1.26 10-Q · filed 2017-05-09 |
| 2016-12-31 | $1.10 10-K · filed 2017-03-08 |
| 2016-09-30 | $0.99 10-Q · filed 2016-11-10 |
| 2016-06-30 | $0.93 10-Q · filed 2016-08-12 |
| 2016-03-31 | $0.90 10-Q · filed 2016-05-13 |
| 2015-12-31 | $0.87 10-K · filed 2016-03-28 |
| 2015-09-30 | $0.77 10-Q · filed 2015-11-10 |
| 2015-06-30 | $0.67 10-Q · filed 2015-08-13 |
| 2015-03-31 | $0.43 10-Q · filed 2015-05-13 |
| 2014-12-31 | $0.25 10-K · filed 2015-02-10 |
| 2014-09-30 | $0.19 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |